- All proposed resolutions were voted according to management’s recommendations;
- Bpifrance Participations, represented by Maïlys Ferrere, and Pr. Jean-Charles Soria were appointed to the Supervisory Board;
- Change in management team with departure of Nicolai Wagtmann and promotion of Yannis Morel to oversee the strategy of Innate’s growing portfolio of clinical and preclinical assets.
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces the results of the voting by shareholders at the Annual General Meeting (“AGM”) which took place on June 23, 2017, in Marseille, France. All resolutions were voted in accordance with the management team’s recommendations.
A total of 21,337,187 votes was cast out of 53,994,029 shares with voting rights, representing a quorum of 39.517%.
Details of the votes are available on the Company’s website, in the Annual General Meeting 2017 section.
During the AGM:
- Board members’ mandates were renewed for a two-year period;
- Pr. Jean-Charles Soria and Bpifrance Participations, represented by Maïlys Ferrere, were appointed as new members of the Supervisory Board for a two-year period;
- Olivier Martinez was appointed Observer of the Supervisory Board for a one-year period.
The Company also announces that Nicolai Wagtmann, PhD, Executive Vice-President and Chief Scientific Officer of Innate Pharma, and member of the Executive Board, has resigned due to personal reasons to pursue a career in the US. A recruitment process is underway and an announcement about successor will be made in due time.
Furthermore the Company is pleased to announce that Yannis Morel, PhD, Executive Vice President, Chief Business Officer and member of the Executive Board, has been promoted to EVP Products portfolio strategy & Business development and will oversee the strategy of the Innate’s growing portfolio of clinical and preclinical assets. Yannis will also assume the role as interim CSO.
Hervé Brailly, Chairman of the Supervisory Board of Innate Pharma, said: “We are pleased to welcome both Maïlys and Jean-Charles to the Supervisory Board. Their combined experience from the field of immuno-oncology and corporate finance and strategy will be a great asset to the Company”. He added: “On behalf of the Board and management team, Mondher Mahjoubi and I would like to thank Nicolai for his commitment and contribution to the Company. Since joining Innate Pharma in 2013 he has successfully overseen the development and expansion of the Company’s novel drug pipeline and we all wish him well in his future endeavors. We are also delighted to congratulate Yannis on his new strategic responsibility at this exciting time for the Company and look forward to his continued strong contribution within our leadership team.”
Maïlys Ferrère is Director of the Large Venture Investment team within the Innovation Division of Bpifrance. Large Venture’s mission is to provide long term capital to innovative French companies in areas with very strong growth with the goal of creating world leaders. The portfolio currently includes 30 companies in life sciences, digital and environmental technologies. Prior to this position, Maïlys Ferrère was an Investment Director at the Strategic Investment Fund between 2009 and 2012. She previously had a career in banking, focusing on equity capital markets in various financial institutions. Maïlys Ferrère is a member of the Boards of Directors or Supervisory boards of the following companies: DBV, Valneva SE, Pixium, Gensight and Euronext Paris.
Professor Jean-Charles Soria is a medical oncologist and a Professor of Medicine and Medical Oncology at South-Paris University. He is a full-time cancer specialist at Institut Gustave Roussy. Professor Soria trained as a medical oncologist and obtained the Silver medal from Paris Medical School in 1997. He gained a postgraduate degree and a PhD degree in molecular biology (fundamental basis of oncogenesis) in 2001, and completed his training with a two-year post-doctoral fellowship at MD Anderson Cancer Center, Houston, USA, where he has held an Adjunct Professorship since 2012. Professor Soria is also a member of the thoracic pathology committee at Gustave Roussy Cancer Center. He is a recognized expert on targeted therapies, immunotherapy and lung cancer. His main research interests are: early clinical development, pharmacodynamic biomarkers, lung cancer, immunotherapy and personalized medicine. He is also involved in translational research aspects related to precision medicine and tumor progression notably in lung cancer models (INSERM unit 981).
The Supervisory Board of Innate Pharma is now composed of:
- Hervé Brailly, Chairman
- Irina Staatz-Granzer, Vice-Chairman
- Gilles Brisson
- Véronique Chabernaud
- Bpifrance Participations, represented by Maïlys Ferrere
- Novo Nordisk A/S, represented by Karsten Munk Knudsen
- Patrick Langlois
- Jean-Charles Soria
- Olivier Martinez, Observer